Josh Weiner
Mark Cuban, the billionaire investor and cofounder of Cost Plus Drugs, laid out a five-step plan to Texas lawmakers aimed at tackling America’s healthcare affordability crisis, which he noted has left a record 51% of US adults unable to reliably afford quality care.
At the center of Cuban’s proposal is a call to let insured patients choose the cheapest option for a prescription without financial penalty, allowing someone to pay $100 through a service like Cost Plus Drugs instead of $500 through insurance, while still having that spending count toward their deductible and out-of-pocket maximum.
Cuban also pushed for standardized contracts for pharmacy benefit managers and third-party administrators, pointing out that just three PBMs, CVS Caremark, Cigna’s Express Scripts and UnitedHealth’s OptumRx, handle roughly 80% of all US drug claims. He described the current contractual arrangements between these middlemen and other healthcare players as “contractual terrorism.”
The remaining steps call for mandatory public disclosure of pricing data, including rebates, fees, guarantees and affiliate compensation, for any program funded by taxpayers such as Medicare and Medicaid, along with eliminating gag clauses that prevent pricing transparency and giving regulators stronger enforcement authority to act on violations.
Transparency runs as the common thread through nearly all five proposals, reflecting Cuban's broader argument that much of the dysfunction in US drug pricing stems not from the cost of medicines themselves but from opaque intermediary arrangements that obscure where money actually goes.
Cuban's remarks add a prominent business voice to the ongoing debate over PBM reform, a topic that has drawn bipartisan scrutiny in Washington as lawmakers weigh how directly to intervene in an industry that plays an outsized role in determining what American patients ultimately pay for prescription drugs.
